Oncoteq
Private Company
Funding information not available
Overview
Oncoteq AG is a privately held, AI-powered oncology biotech founded in 2022 and based in Zug, Switzerland. The company utilizes a proprietary AI platform to identify and develop promising but potentially overlooked oncology therapeutics, aiming to transform drug development by combining AI-driven insights with a flexible company-builder model. With a small team of over 10 employees and strategic backing from its parent company, Cureteq AG, Oncoteq is advancing a pipeline of three clinical-stage assets while actively engaging with partners and investors in the biotech ecosystem. Its strategy centers on driving assets beyond key value inflection points through targeted development and partnerships.
Technology Platform
AI-powered platform to identify optimal applications for molecules and de-risk clinical development, focusing on unlocking value from unattended oncology assets. Integrated with a flexible biotech company-builder model.
Opportunities
Risk Factors
Competitive Landscape
Oncoteq competes in the rapidly growing field of AI-enabled drug discovery and development, facing competition from both pure-play AI biotechs (e.g., Exscientia, Recursion) and internal initiatives at large pharma. Its differentiation lies in its specific focus on late-stage preclinical/clinical asset optimization within oncology and its lean, asset-centric company-builder model.